A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor G1147211 given as a 72-h continuous infusion
1998

Study of G1147211 in Cancer Treatment

Sample size: 44 publication Evidence: moderate

Author Information

Author(s): L Paz-Ares, R Kunkal, D DeMaria, J Cassidy, M Alden, P Beranek, S Kaye, D Littlefield, D Reilly, S Depee, P Wissel, C Twelves, P O'Dwyer

Primary Institution: University of Glasgow

Hypothesis

The study aims to determine the maximum tolerated dose of G1147211 as a 72-hour infusion and to describe its pharmacokinetics and pharmacodynamics.

Conclusion

G1147211 is well tolerated as a 72-hour infusion with manageable side effects and shows promising anti-tumor activity.

Supporting Evidence

  • Three partial responses lasting 8-34+ weeks were noted in patients with ovarian, colon, and breast carcinomas.
  • Neutropenia was dose limiting at 2.0 mg m-2 day-1 in minimally pretreated patients.
  • Mean steady-state concentrations of G1147211 increased with dose over a range of 0.25-1.24 ng ml-1.

Takeaway

Doctors tested a new cancer drug called G1147211 to see how much they can give safely, and it seems to help some patients with cancer.

Methodology

A single-arm, rising-dose study where patients received 72-hour infusions of G1147211 at varying doses.

Potential Biases

Potential bias due to the single-arm design and lack of control group.

Limitations

The study had a small sample size and was limited to patients with advanced cancer.

Participant Demographics

Patients had advanced cancer, with a median age of 60 years, and included equal numbers of men and women.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication